ALEC Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Alector Inc (ALEC) is not a strong buy at this time for a beginner investor with a long-term strategy. The stock is facing significant financial challenges, insider selling, and a lack of strong technical or proprietary trading signals. While there are some promising advancements in its drug pipeline, the recent financial performance and market sentiment do not support a confident investment decision.
The MACD is negatively expanding (-0.0182), RSI is neutral at 35.456, and the moving averages are bullish (SMA_5 > SMA_20 > SMA_200). However, the stock is trading near its support level (S1: 1.993), and the price has dropped significantly (-7.91%) in the last session, indicating bearish momentum.
Alector's advancements in its ABC brain-delivery platform and drug pipeline, such as AL137 and AL050, show potential for treating neurodegenerative diseases. The siRNA program's success in tau mRNA knockdown is another promising development.
Significant insider selling (586.08% increase in the last month), a sharp revenue decline (-88.50% YoY in Q4 2025), and the failure of Latozinemab have raised concerns about the company's financial health and drug pipeline. Additionally, the stock's recent price drop and lack of proprietary trading signals indicate weak investor confidence.
In Q4 2025, revenue dropped significantly to $6.24 million (-88.50% YoY), while net income worsened to -$37.27 million (+1696.87% YoY). EPS also declined to -$0.34 (+1600.00% YoY). Despite a gross margin of 100%, the financials highlight substantial challenges.
Morgan Stanley recently raised the price target to $0.90 from $0.75 but maintained an Underweight rating, reflecting cautious sentiment. The firm acknowledges challenges in the biotech sector but sees potential for mid-cap biotech outperformance in 2026.
